ANIX - Anixa Biosciences Inc Stock Price, Fair Value and News

3.05USD+0.16 (+5.54%)Market Closed

Market Summary

USD3.05+0.16

Market Closed

5.54%

ANIX Alerts

1 major insider buys recently.

ANIX Stock Price

View Fullscreen

ANIX RSI Chart

ANIX Valuation

Market Cap

97.6M

Price/Earnings (Trailing)

-8.42

Price/Sales (Trailing)

387.13

EV/EBITDA

-8.65

Price/Free Cashflow

-13.6

ANIX Price/Sales (Trailing)

ANIX Profitability

EBT Margin

-4548.42%

Return on Equity

-49.08%

Return on Assets

-47.61%

Free Cashflow Yield

-7.35%

ANIX Fundamentals

ANIX Revenue

Revenue (TTM)

210.0K

ANIX Earnings

Earnings (TTM)

-11.6M

Earnings Growth (Yr)

-37.19%

Earnings Growth (Qtr)

3.56%

Breaking Down ANIX Revenue

Last 7 days

3.7%

Last 30 days

28.7%

Last 90 days

-5.6%

Trailing 12 Months

-14.1%

How does ANIX drawdown profile look like?

ANIX Financial Health

Current Ratio

14.4

Debt/Equity

0.08

Debt/Cashflow

-4.09

ANIX Investor Care

Shares Dilution (1Y)

3.33%

Diluted EPS (TTM)

0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	411.3K	310.7K	210.0K
2021	763.0K	513.0K	513.0K	512.0K
2019	0	1.4M	612.5K	250.0K
2018	0	918.8K	1.5M	1.1M
2017	0	0	331.3K	362.5K
2016	0	0	4.8M	300.0K
2015	0	0	0	9.3M
2014	0	0	0	0
2013	0	0	0	388.9K
2012	1.4M	1.6M	1.4M	940.0K
2011	798.8K	866.9K	935.1K	1.0M
2010	0	0	0	730.7K

Get all data in R, Python etc through our Historical Stock Data APIs

About Anixa Biosciences Inc

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

CEO	Dr. Amit Kumar Ph.D.
WEBSITE	anixa.com
INDUSTRY	Biotechnology
EMPLOYEES	4

Anixa Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Anixa Biosciences Inc? What does ANIX stand for in stocks?

ANIX is the stock ticker symbol of Anixa Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Anixa Biosciences Inc (ANIX)?

As of Fri Jul 26 2024, market cap of Anixa Biosciences Inc is 97.62 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIX stock?

You can check ANIX's fair value in chart for subscribers.

Is Anixa Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether ANIX is over valued or under valued. Whether Anixa Biosciences Inc is cheap or expensive depends on the assumptions which impact Anixa Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIX.

What is Anixa Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ANIX's PE ratio (Price to Earnings) is -8.42 and Price to Sales (PS) ratio is 387.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIX PE ratio will change depending on the future growth rate expectations of investors.